Dangshe Ma

Progenics Pharmaceuticals, Inc.

$5,789,789

Attributed

$5,789,789

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.4M · FY2005–08

$2M$1.5M$1M$500K$0

'05

'06

'07

'08

Funding mix

By agency

NIH$5,789,789 · 4

By mechanism

R44$4,765,978 · 2

R43$1,023,811 · 2

Top collaborators

No co-investigators on record.

Most similar at Progenics Pharmaceuticals, Inc.

Same institution · by research overlap

Daniel C Pevear$8,250,851
Glen Andrew Coburn$12,617,543
William C Olson$17,385,230
Gerald P Donovan$9,061,908
Paul J Maddon$8,313,643

Others in their field

Top investigators on “Immunologic Substance Development /Preparation”

Maureen Howard · Chemocentryx, Inc.$7,605,790
Israel Lowy · Medarex, Inc.$6,431,762
Arthur M. Krieg · University Of Pennsylvania$6,250,700
William C Olson · Progenics Pharmaceuticals, Inc.$5,661,660
Vincent Strout · Elusys Therapeutics, Inc.$5,000,000
Susan B Zolla-Pazner · New York University School Of Medicine$3,671,666

Research focus

Immunologic Substance Development /PreparationMonoclonal AntibodyLaboratory MouseNeoplasm /Cancer RadioimmunotherapyGlycoproteinsHormonesHuman Monoclonal AntibodiesDrug KineticsExtracellular DomainEpitopesChemotherapyGlutamate Carboxypeptidase Ii, HumanAndrogensHormone Refractory Prostate CancerCancer EtiologyCytoplasmCancer CellCollaborationsAntibodiesDoseAffinityEpithelial CellsCessation Of LifeAblation